ArticlePharmaceuticals (Basel, Switzerland)2025

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) Regimen.

Esraa K Abdelfattah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.